Patents by Inventor Ianthe Pitout

Ianthe Pitout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Retinitis pigmentosa treatment
    Patent number: 12649922
    Abstract: An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.
    Type: Grant
    Filed: July 31, 2024
    Date of Patent: June 9, 2026
    Assignee: Vision Pharma PTY LTD
    Inventors: Sue Fletcher, Ianthe Pitout, Janya Grainok, Steve D. Wilton, Fred K. Chen
  • Treatment of optic atrophy
    Patent number: 12637676
    Abstract: An isolated or purified antisense oligomer for modulating mRNA translation of the OPA1 gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.
    Type: Grant
    Filed: October 1, 2021
    Date of Patent: May 26, 2026
    Assignee: PYC Therapeutics Limited
    Inventors: Janya Grainok, Ianthe Pitout, Sasiwimon Utama, Kim Rice
  • Retinitis pigmentosa treatment
    Patent number: 12559747
    Abstract: An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: February 24, 2026
    Assignee: VISION PHARMA PTY LTD
    Inventors: Sue Fletcher, Ianthe Pitout, Jayna Grainok, Steve D. Wilton, Fred K. Chen
  • Novel Retinitis Pigmentosa Treatment
    Publication number: 20250066782
    Abstract: An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.
    Type: Application
    Filed: July 31, 2024
    Publication date: February 27, 2025
    Inventors: Sue Fletcher, Ianthe Pitout, Jayna Grainok, Steve D. Wilton, Fred K. Chen
  • TREATMENT OF OPTIC ATROPHY
    Publication number: 20230407310
    Abstract: An isolated or purified antisense oligomer for modulating mRNA translation of the OPAL gene transcript or part thereof which has a modified backbone structure and sequences with at least 75% sequence identity to the isolated or purified antisense oligomer.
    Type: Application
    Filed: October 1, 2021
    Publication date: December 21, 2023
    Inventors: Fred Chen, Ianthe Pitout, Janya Grainok, Sasiwimon Utama, Kim Rice
  • Novel Retinitis Pigmentosa Treatment
    Publication number: 20220298506
    Abstract: An isolated or purified antisense oligomer for modifying pre-mRNA splicing in the CNOT3 gene transcript or part thereof.
    Type: Application
    Filed: May 25, 2020
    Publication date: September 22, 2022
    Inventors: Sue Fletcher, Ianthe Pitout, Jayna Grainok, Steve D. Wilton, Fred K. Chen